Early prostate-specific antigen response post-abiraterone as predictor of overall survival in metastatic castrate-resistant prostate cancer

BACKGROUND: Abiraterone is an important agent in the treatment of advanced prostate cancer. Early changes in prostate-specific antigen while on abiraterone in patients with metastatic castrate-resistant prostate cancer potentially have financial and health implications for patients. Limited data is...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:BMC Cancer
Main Authors: Schiff, Joshua P., Cotogno, Patrick, Feibus, Allison, Steinwald, Peter, Ledet, Elisa, Lewis, Brian, Sartor, Oliver
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6544996/
https://ncbi.nlm.nih.gov/pubmed/31151428
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-019-5729-7
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki